S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
'Knock at the Cabin' knocks off 'Avatar' at the box office
Ally Financial expands NASCAR spend with 2 new partnerships
Top-Rated Stocks  
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$155.64
-0.76 (-0.49%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$155.29
▼
$158.42
50-Day Range
$149.93
▼
$160.47
52-Week Range
$125.36
▼
$169.98
Volume
402,385 shs
Average Volume
406,794 shs
Market Capitalization
$9.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$202.55

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
30.1% Upside
$202.55 Price Target
Short Interest
Healthy
4.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.57mentions of Jazz Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.97 M Sold Last Quarter
Proj. Earnings Growth
6.13%
From $15.18 to $16.11 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

82nd out of 1,025 stocks

Pharmaceutical Preparations Industry

32nd out of 498 stocks

See Top Rated MarketRank™ Stocks Here
JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

February 3, 2023 | marketwatch.com
Idiopathic Hypersomnia Treatment Market for the Period 2023 To 2028: With Top Countries Data Analysis and Latest Development Plan
February 2, 2023 | benzinga.com
CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 31, 2023 | finance.yahoo.com
Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
January 29, 2023 | marketwatch.com
Medical Asparaginase Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028
January 26, 2023 | finance.yahoo.com
FDA says it will not regulate CBD and calls on Congress to act
January 25, 2023 | finance.yahoo.com
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
January 23, 2023 | marketwatch.com
Sulfanilamide Market To Show Incredible Growth And Forecast By 2028 Segment, Privacy Tools And Key Players Information
February 5, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 23, 2023 | marketwatch.com
Nonnarcotic Analgesics Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2029
January 23, 2023 | finanznachrichten.de
Lexaria Bioscience Corp.: Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
January 19, 2023 | msn.com
Jazz Pharma, Zymeworks post 84% overall survival for GIT cancer candidate
January 19, 2023 | finance.yahoo.com
Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals
January 19, 2023 | finance.yahoo.com
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
January 19, 2023 | finance.yahoo.com
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
January 18, 2023 | thestreet.com
Jazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings Miss
January 16, 2023 | marketwatch.com
Clozapine Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook Report
January 14, 2023 | marketwatch.com
Lewy Body Dementia Treatment Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028
January 13, 2023 | benzinga.com
Psychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViews
January 12, 2023 | marketwatch.com
Cytokine Storm Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028
January 11, 2023 | finance.yahoo.com
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
January 6, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)
January 6, 2023 | benzinga.com
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
January 3, 2023 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023 | finance.yahoo.com
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022 | msn.com
Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data
December 21, 2022 | finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
CIK
1232524
Web
www.jazzpharma.com
Phone
(531) 634-7800
Fax
353-1634-7850
Employees
3,200
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$202.55
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+30.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
10.25
P/E Growth
0.9
Net Income
$-329,670,000.00
Net Margins
-0.52%
Pretax Margin
-2.17%
Return on Equity
30.71%
Return on Assets
9.10%

Debt

Debt-to-Equity Ratio
2.07
Current Ratio
3.16
Quick Ratio
2.27

Sales & Book Value

Annual Sales
$3.09 billion
Price / Sales
3.17
Cash Flow
$22.96 per share
Price / Cash Flow
6.78
Book Value
$64.51 per share
Price / Book
2.41

Miscellaneous

Outstanding Shares
62,970,000
Free Float
60,195,000
Market Cap
$9.80 billion
Optionable
Optionable
Beta
0.71

Social Links


Key Executives

  • Bruce C. CozaddBruce C. Cozadd
    Chairman & Chief Executive Officer
  • Daniel N. Swisher
    President
  • Christopher John ToveyChristopher John Tovey
    Chief Operating Officer & Executive Vice President
  • Renée D. Galá
    Chief Financial Officer & Executive Vice President
  • Robert Iannone
    Chief Medical Officer, EVP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

10 brokerages have issued twelve-month target prices for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they anticipate the company's share price to reach $202.55 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 on January 1st, 2023. Since then, JAZZ shares have decreased by 2.3% and is now trading at $155.64.
View the best growth stocks for 2023 here.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings data on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 EPS for the quarter, topping analysts' consensus estimates of $4.35 by $0.18. The specialty pharmaceutical company had revenue of $940.65 million for the quarter, compared to the consensus estimate of $939.88 million. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive trailing twelve-month return on equity of 30.71%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share guidance of $17.20-$17.85 for the period, compared to the consensus EPS estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Todd Asset Management LLC (0.28%), Allspring Global Investments Holdings LLC (0.20%), New York State Common Retirement Fund (0.17%) and Bank of Montreal Can (0.15%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $155.64.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.80 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 2/5/2023 by MarketBeat.com Staff